Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T96760
|
||||
Former ID |
TTDI02078
|
||||
Target Name |
Growth differentiation factor-5
|
||||
Gene Name |
GDF5
|
||||
Synonyms |
CDMP1; Cartilagederived morphogenetic protein 1; Growth/differentiation factor 5; Radotermin; GDF5
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Periodontal disease [ICD10: K05] | ||||
Function |
Required to prevent excessive muscle loss upon denervation. This function requires SMAD4 and is mediated by phosphorylated SMAD1/5/8 (By similarity). Could be involved in bone and cartilage formation. Chondrogenic signaling is mediated by the high-affinity receptor BMPR1B. Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes.
|
||||
BioChemical Class |
Growth factor
|
||||
UniProt ID | |||||
Sequence |
MRLPKLLTFLLWYLAWLDLEFICTVLGAPDLGQRPQGTRPGLAKAEAKERPPLARNVFRP
GGHSYGGGATNANARAKGGTGQTGGLTQPKKDEPKKLPPRPGGPEPKPGHPPQTRQATAR TVTPKGQLPGGKAPPKAGSVPSSFLLKKAREPGPPREPKEPFRPPPITPHEYMLSLYRTL SDADRKGGNSSVKLEAGLANTITSFIDKGQDDRGPVVRKQRYVFDISALEKDGLLGAELR ILRKKPSDTAKPAAPGGGRAAQLKLSSCPSGRQPASLLDVRSVPGLDGSGWEVFDIWKLF RNFKNSAQLCLELEAWERGRAVDLRGLGFDRAARQVHEKALFLVFGRTKKRDLFFNEIKA RSGQDDKTVYEYLFSQRRKRRAPLATRQGKRPSKNLKARCSRKALHVNFKDMGWDDWIIA PLEYEAFHCEGLCEFPLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRLSPISILFID SANNVVYKQYEDMVVESCGCR |
||||
Drugs and Mode of Action | |||||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
Pathways | |||||
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
TGF-beta signaling pathway | |||||
Hippo signaling pathway | |||||
NetPath Pathway | IL1 Signaling Pathway | ||||
TGF_beta_Receptor Signaling Pathway | |||||
PANTHER Pathway | TGF-beta signaling pathway | ||||
Reactome | Molecules associated with elastic fibres | ||||
WikiPathways | Differentiation Pathway | ||||
Elastic fibre formation | |||||
References | |||||
Ref 523045 | ClinicalTrials.gov (NCT01124006) A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.